VANCOUVER, British Columbia, Aug. 10, 2011 (GLOBE NEWSWIRE) -- Immune Network Ltd., (Pink Sheets:IMMFF), reports that its business partner Immunitor company has launched a Phase 2 clinical trial of a novel anti-tuberculosis immunotherapy consisting of orally-delivered, heat-inactivated Mycobacterium vaccae. The new tableted preparation was formulated according to clinically validated proprietary technology developed by Immunitor company.
